Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer

Blood

Volumn 107, Issue 12, 2006, Pages 4954-4960

  Slager, Elisabeth H ^a   Honders, M Willy ^b   Van Der Meijden, Edith D ^b   Van Luxemburg Heijs, Simone A P ^b   Kloosterboer, Freke M ^b   Kester, Michel G D ^b   Jedema, Inge ^b   Marijt, W A Erik ^b   Schaafsma, M Ron ^b   Willemze, Roel ^b   Falkenburg, J H Frederik ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; COMPLEMENTARY DNA; ENDOTHELIAL CELL GROWTH FACTOR; HISTIDINE; MINOR HISTOCOMPATIBILITY ANTIGEN; TETRAMER; THYMIDINE PHOSPHORYLASE;

ALLELE; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR CLONING; MULTIPLE MYELOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL TRANSPLANTATION;

EID: 33745080319     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3883     Document Type: Article

References (44)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
2. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: vaccines for solid tumours. Lancet Oncol. 2004;5:681-689.
3. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
4. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
5. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
6. Falkenburg JH, van de Corput L, Marijt EW, Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol. 2003;31:743-751.
7. Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997;90:2529-2534.
8. den Haan JMM, Meadows LM, Wang W, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 1998;279:1054-1057.
9. Denhaan JMM, Sherman NE, Blokland E, et al. Identification of a graft-versus-host disease-associated human minor histocompatibility antigen. Science. 1995;268:1476-1480.
10. Pierce RA, Field ED, Mutis T, et al. The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J Immunol. 2001;167:3223-3230.
11. Akatsuka Y, Nishida T, Kondo E, et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med. 2003;197:1489-1500.
12. Kloosterboer FM, Luxemburg-Heijs SA, van Soest RA, et al. Minor histocompatibility antigen-specific T cells with multiple distinct specificities can be isolated by direct cloning of IFNgamma-secreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion. Leukemia. 2005;19:83-90.
13. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood. 2004;103:2677-2682.
14. Kloosterboer FM, Luxemburg-Heijs SA, van Soest RA, et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia. 2004;18:798-808.
15. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics. 1995;42:455-500.
16. Burrows SR, Kienzle N, Winterhalter A, Bharadwaj M, Altman JD, Brooks A. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol. 2000;165:6229-6234.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
18. De Plaen E, Lurquin C, Lethe B, et al. Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. Methods. 1997;12:125-142.
19. Su AI, Cooke MP, Ching KA, et al. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A. 2002;99:4465-4470.
20. Kocaefe YC, Erdem S, Ozguc M, Tan E. Four novel thymidine phosphorylase gene mutations in mitochondrial neurogastrointestinal encephalomyopathy syndrome (MNGIE) patients. Eur J Hum Genet. 2003;11:102-104.
21. Shastri N, Schwab S, Serwold T. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu Rev Immunol. 2002;20:463-493.
22. Torikai H, Akatsuka Y, Miyazaki M, et al. A novel HLA-A*3303- restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene. J Immunol. 2004;173:7046-7054.
23. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064-3073.
24. Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol. 2001;28:565-569.
25. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6:3111-3116.
26. Bruno B, Rotta M, Giaccone L, et al. New drugs for treatment of multiple myeloma. Lancet Oncol. 2004;5:430-442.
27. Childs RW, Barrett J. Nonmyeloablative allogeneic immunotherapy for solid tumors. Annu Rev Med. 2004;55:459-475.
28. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T. Expression of platelet-derived endothelial-cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer. 1995;64:79-82.
29. Imazano Y, Takebayashi Y, Nishiyama K, et al. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol. 1997;15:2570-2578.
30. Tokunaga Y, Hosogi H, Hoppou T, Nakagami M, Tokuka A, Ohsumi K. Prognostic value of thymidine phosphorylase/platelet-derived endothelial-cell growth factor in advanced colorectal cancer after surgery: evaluation with a new monoclonal antibody. Surgery. 2002;131:541-547.
31. Fujiwaki R, Hata K, Iida K, Maede Y, Koike M, Miyazaki K. Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis. J Clin Pathol. 1999;52:598-603.
32. Reynolds K, Farzaneh F, Collins WP, et al. Association of ovarian malignancy with expression of platelet-derived endothelial-cell growth factor. J Natl Cancer Inst. 1994;86:1234-1238.
33. Eda H, Fujimoto K, Watanabe S, et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol. 1993;32:333-338.
34. Griffiths L, Dachs GU, Bicknell R, Harris AL, Stratford IJ. The influence of oxygen tension and pH on the expression of platelet-derived endothelial-cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res. 1997;57:570-572.
35. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998;4:1013-1019.
36. Endo M, Shinbori N, Fukase Y, et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5- fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer. 1999;83:127-134.
37. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5:2948-2953.
38. Ikeda R, Furukawa T, Kitazono M, et al. Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose. Biochem Biophys Res Commun. 2002;291:806-812.
39. Kitazono M, Takebayashi Y, Ishitsuka K, et al. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Commun. 1998;253:797-803.
40. Mori S, Takao S, Ikeda R, et al. Thymidine phosphorylase suppresses Fas-induced apoptotic signal transduction independent of its enzymatic activity. Biochem Biophys Res Commun. 2002;295:300-305.
41. Mori S, Takao S, Ikeda R, et al. Role of thymidine phosphorylase in Fas-induced apoptosis. Hum Cell. 2001;14:323-330.
42. Ikeda R, Furukawa T, Mitsuo R, et al. Thymidine phosphorylase inhibits apoptosis induced by cisplatin. Biochem Biophys Res Commun. 2003;301:358-363.
43. Fox SB, Moghaddam A, Westwood M, et al. Platelet-derived endothelial-cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol. 1995;176:183-190.
44. National Center for Biotechnology Information. BLAST: Basic Local Alignment Search Tool. http://www.ncbi.nlm.nih.gov/BLAST/. Accessed November 2004.